Menopur (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). FSH stimulates granulosa cells to proliferate and produce estrogen, while LH supports theca‑cell androgen production that is converted to estrogen. Together they promote follicular growth, maturation, and the hormonal environment needed for ovulation.

The dose of Menopur is individualized. A qualified prescriber determines the amount and frequency based on the patient’s ovarian reserve, treatment protocol, and response monitoring. Dosing may be adjusted during the stimulation cycle according to ultrasound and hormone measurements.

Menopur is not indicated for use during an established pregnancy and is contraindicated in pregnant women. Limited data exist for breastfeeding; therefore, it is generally avoided while nursing unless the benefits outweigh potential risks as assessed by a healthcare professional.

To order Menopur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Menopur (menotropin) is a urinary‑derived FSH/LH preparation, whereas many clinics use recombinant FSH (e.g., follitropin alfa) that contains only FSH activity. Menotropin provides both FSH and LH, which can be advantageous in certain protocols, but recombinant products offer higher purity and more consistent dosing.

Menopur must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. Once reconstituted, use the solution promptly according to the manufacturer’s instructions.

Menopur is supplied as a lyophilized powder for injection. After reconstitution with the appropriate diluent, it is administered by intramuscular or subcutaneous injection, typically once daily during the stimulation phase, under the supervision of a fertility specialist.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause fluid accumulation and organ dysfunction, multiple pregnancy, thromboembolic events, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for early signs of these complications.

Menopur is contraindicated in women who are already pregnant, have known hypersensitivity to menotropin or any excipients, have uncontrolled thyroid disease, active ovarian cysts, or a history of severe OHSS. Caution is also advised for patients with hormone‑sensitive cancers or significant cardiovascular disease.